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ABSTRACT
Purpose Developing microbicides for topical epithelial appli-
cations is extremely challenging, as evidenced by the scarcity of
approved products even after decades of research. Chemical
enhancers, including surfactants, are known to be effective
antimicrobial agents but are typically toxic towards epithelial
cells. Here, we report on the discovery of unique surfactant
formulations with improved safety and efficacy profile for
epithelial applications, via a combination of high throughput
screening techniques.
Methods Over three-hundred formulations derived from nine
surfactants were screened for antibacterial properties against E.
coli in vitro. A subset of these formulations showed high
antibacterial activity and was screened for cytotoxicity in vitro.
Formulations showing high antibacterial activity and reduced
cytotoxicity compared to their individual components were
tested for efficacy against B. thailendensis,am o d e lf o r
melioidosis-causing B. pseudomallei.
Results Lead formulations showed lower toxicity towards
epidermal keratinocytes, with LC50 values up to 3.5-fold higher
than their component surfactants, while maintaining antibacte-
rial efficacy against B. thailendensis.
Conclusions Our results demonstrate that such a combinato-
rial screening approach can be used for designing safe and
potent microbicides for epithelial applications.
KEY WORDS combinatorial.highthroughput.microbicide.
safe.topical
INTRODUCTION
Skin acts as a possible port of entry for numerous micro-
organisms. Human skin is regularly colonized by a number
of non-pathogenic gram-positive bacteria, including differ-
ent species of Staphylococci, Sarcina and Corynbacteria groups
(1,2). Gram-negative skin-resident bacteria are found in
lesser abundance and include Mima, Herellea, Acinetobacter
and Aerobacter. In addition, skin acts as a transient harbor to
pathogenic bacteria or viruses to which it gets exposed. The
topmost layer of skin, stratum corneum, provides a passive
but formidable barrier to foreign entities and limits the habitat
of these organisms to superficial layers. However, the barrier
presented by stratum corneum can break down in the event of
accidental cuts, bruises or pathological conditions, such as
atopic dermatitis. The access to the underlying skin epitheli-
um, epidermis, gives native and non-native skin flora the
opportunity to infect the deeper layers of skin.
Epidermis is a highly potent immune organ and contains
numerous resident cellular components of immune system,
including keratinocytes, dendritic cells, mast cells, tissue
macrophages and T lymphocytes (3,4). Keratinocytes form
the bulk of epidermal cellular population and orchestrate
the innate immune response against invading pathogens by
secreting pro-inflammatory cytokines and chemokines as
well as by directly killing pathogens via secretion of
antimicrobial peptides. The effectiveness of the epidermis
in combating infections limits the number of skin infections,
but does not completely eliminate them. Further, immuno-
suppressive conditions, such as atopic dermatitis, are
coupled with high incidence of skin infections by bacteria
and fungi, including Staphylococcus aureus, Staphylococcus
epidermidis and Malassezia furfur (5).
As skin harbors several different strains of bacteria,
frequent and uncontrolled use of antibiotics to treat
pathological skin conditions increases the risk of emergence
of antibiotic-resistant strains (6–8). Further, there is an
increasing awareness regarding the need to sanitize skin for
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catheter insertion (9,10). Sanitization of skin and other
body surfaces, such as nasal mucosa, will also prove highly
beneficial during outbreaks of viral infections, such as
influenza. Viral pathogens can have extended residence
time on skin, thus increasing the likelihood of person-to-
person transfer. Thus, there is a need to supplement the
innate immune barriers with intelligently designed small-
molecule-based topical antimicrobial formulations as an
alternative preventive measure.
Surfactants are one class of small molecules which have
been well established as highly effective microbicides for the
last several decades (11–13). Since the last decade, significant
research and development efforts have been directed towards
using nonionic surfactants as mucosal virucidal agents, but
high levels of cytotoxicity continue to plague the current
approach of using single surfactants (14,15). The difficulty
and complexity of discovering potent and safe microbicides is
further evident from the fact that no safe microbicide has
been developed for co-application on pathogens and viable
human cells for any of the body surfaces.
Previously, we have successfully employed combinatorial
high-throughput methods for finding unique combinations
of small molecules, including surfactants, for needle-free
transdermal drug and vaccine delivery (16–18). Here, those
design principles are extended to the search of unique
antimicrobial formulations which would be safe for applica-
tion over large body surface areas. Using E. coli as a model
gram-negative pathogen and human epidermal keratinocytes
as a model epithelial cell line, a library of binary chemical
formulations was screened for discovering unique combina-
tions with high antibacterial efficacy and low toxicity.
MATERIALS AND METHODS
Generation of Chemical Formulation Library
Three surfactants were selected from each of the following
chemical categories: (a) anionic surfactants, (b) cationic
surfactants, (c) nonionic surfactants. The details, including
full name, abbreviations used in this text and CAS registry
numbers, are given in Table I. SLS, CPC, ALS, T20 and
PEG were purchased from Sigma Aldrich (St. Louis, MO).
CTC and BZK were purchased from TCI America
(Portland, OR). TRL and S20 were purchased from Fisher
Scientific (Fairlawn, NJ). Surfactant selection was primarily
based on documented antibacterial activity and approval
for usage in topical products by FDA, as per their GRAS
(Generally Recognized as Safe) list status. All surfactants
were paired with every other surfactant to form 36 binary
pairs. Further, the weight fraction of components in each
binary was varied from 0 to 1, in steps of 0.1 each, to
create 11 unique combinations. Thus, the total library
consisted of 324 unique binary formulations. Each
formulation was tested at total concentrations of 0.2%,
0.1%, 0.05% and 0.025% w/v. The value of total
concentration was decided based on approved concentra-
tion limits for all the surfactants. Phosphate-buffered
saline and glycerol mixed in equal volumes (1:1 PBS:
Glycerol) was used as the universal solvent system for all
formulations.
Bacterial Strains, Growth Media and Culture Conditions
Wild-type E. coli (strain ER2738) was purchased from New
England Biolabs (Ipswich, MA) and was used as the model
gram-negative pathogen. B. thailendensis (strain E264) was a
gift from Dr. Peggy Cotter (UC Santa Barbara, CA).
Leuria-Bertani (LB) broth (10 g tryptone l
-1, 5 g yeast
extract l
-1, 10 g NaCl l
-1) made in ultrapure water and
sterilized via autoclaving (121°C, 15 min) was used for
culturing E. coli. All components for making the LB broth
were purchased from Fisher Scientific (Fairlawn, NJ).
Precultures were prepared for each experiment by streaking
stock solution (frozen in cryovials at -80°C) on LB agar
plate. After overnight incubation of the plates at 37°C, one
colony was picked and loop-inoculated into a culture tube
containing 5 ml LB broth. The culture tube was incubated
15–18 h at 37°C on a rotary shaker at 250 rpm. At the end
Common name Abbreviation CAS No. Surfactant category
Sodium lauryl sulfate SLS 151-21-3 Anionic
Ammonium lauryl sulfate ALS 2235-54-3 Anionic
Trolamine lauryl sulfate TRL 139-96-8 Anionic
Cetyltrimethylammonium chloride CTC 112-02-7 Cationic
Benzalkonium chloride BZK 139-08-2 Cationic
Cetylpyridinium chloride monohydrate CPC 6004-24-6 Cationic
Sorbitan monolaurate S20 1338-39-2 Nonionic
Polysorbate 20 T20 9005-64-5 Nonionic
Polyethylene glycol 200 PEG 25322-68-3 Nonionic
Table I List of Surfactants Used
in this Study. Common Names,
Abbreviations Used as Part of
Text, Chemical Abstract Service
(CAS) Registry Numbers,
and Surfactant Category are
shown
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culture were transferred into a new culture tube containing
5 ml LB broth and grown to an OD600 value of 0.5 under
the same incubation conditions. The OD600 cultures were
diluted by a factor of 10
3 in LB broth as working
concentration and used immediately to minimize change
in bacterial count. Low-sodium Leuria-Bertani (LSLB)
broth (10 g tryptone l
-1, 5 g yeast extract l
-1, 5 g NaCl l
-1)
made in ultrapure water and sterilized via autoclaving
(121°C, 15 min) was used for culturing B. thailendensis.
Culturing protocol was same as given above for E. coli.
Screening for Antibacterial Efficacy Against E. coli
Antibacterial efficacy of test formulations was quantified
using BacTiter-Glo™ microbial cell viability assay (Promega
Corp., Madison, WI) according to the protocols supplied by
the manufacturer. The assay solution consisted of lysis buffer,
beetle luciferin and recombinant firefly luciferase. Upon
mixing the assay solution with bacterial culture, the bacterial
cells were lysed, followed by extraction of ATP in the culture
solution.Bioluminescencewasproducedasaresultofreaction
between beetle luciferin and recombinant firefly luciferase in
the presence ofATP extractedfromviablebacterial cells.The
level of bioluminescence was directly proportional to the
quantity of ATP present in the solution and was used for
estimation of viable cells.
For the experiments, the E. coli cultures were prepared at
working concentrations as described above and were
dispensed in 96-well cell culture polypropylene plates
(Corning, Lowell, MA) at 240 µl/well. Inoculums in each
well were incubated with 10 µl of test formulations (at 25×
concentration) for 4 h at 37°C. Each formulation was tested
at a final total concentration of 0.2%, 0.1%, 0.05% and
0.025% w/v. Thus, the overall number of formulations
tested was 1,296 or approximately 4,000 experiments
including replicates. At the end of the incubation period,
viable bacterial cells in each well were estimated using
BacTiter-Glo™ assay.
Minimum Inhibitory Concentration (MIC) Estimation
in B. thailendensis
Minimum inhibitory concentration against B. thailendensis
was determined for select formulations. Broth microdilution
method was followed for MIC determination, as per the
protocol published by Wiegand et al (19). Briefly, fresh
cultures were grown on the day of experiment as per the
protocol described in “Bacterial Strains, Growth Media
and Culture Conditions.” The cultures were adjusted to
5.5×10
5 cfu/ml and used within 30 min to minimize
change in bacterial counts. Cultures were dispensed in
96-well cell culture polypropylene plates (Corning, Lowell,
MA) at 90 µl/well. Serial dilutions of test formulations were
made at 10× concentration. Inoculums in each well were
incubated with 10 µl of test formulation dilutions for 18 h at
37°C under humidified conditions. At the end of incuba-
tion period, the plates were visibly inspected for bacterial
growth. Colonies were counted for selected wells by plating
culture dilutions on LSLB plates.
Keratinocyte Cell Culture
Primary epidermal keratinocyte cultures from an adult
human source (HEKa) were purchased from Invitrogen
Corp (Carlsbad, CA) and used for all cytotoxicity experi-
ments. Cells were maintained in a humidified incubator
(37°C, 5% CO2) in EpiLife medium with 60 µM calcium
and phenol red, supplemented with 10 ml/l human
keratinocyte growth supplement, 5 IU/ml penicillin and
5 µg/ml streptomycin. All components of growth media
were purchased from Invitrogen Corp (Carlsbad, CA).
Cells were grown to 70–80% confluence in cell culture
flasks (Corning, Lowell, MA) as per suppliers’ protocols.
Screening for Cytotoxicity
At the end of the growth period, keratinocyte cells were
seeded at a density of 10
4 cells/well in 96-well tissue culture
treated polystyrene plates (Corning, Lowell, MA) and
incubated overnight to allow cell attachment. Cells were
supplied with fresh EpiLife medium (90 µl/well) at the start
of experiment, followed by application of test formulations
(10 µl/well). The final concentration of test formulations in
each well was 0.0001% w/v. This concentration limit was
determined based on the LC50 values of component
surfactants for HEKa cell line, which were determined in
a separate experiment. This concentration was used to
maximize resolution between various surfactants and
facilitate ranking of various formulations in terms of safety.
The actual LC50 values in cells are likely to be much
smaller than those in vivo, since under in vivo conditions,
keratonocytes are expected to experience concentrations
lower than those applied topically, since they are located
farther away from the surface. Hence, the LC50 values
should be used as an indication of relative safety and not
absolute safety. The cells were incubated with the test
formulations for 1 h. At the end of the incubation period,
culture medium was aspirated and replaced with 100 µl of
EpiLife medium without phenol red. Ten microliters of
methyl thiazole tetrazolium solution (5 mg/ml) in phos-
phate-buffered saline was applied to each well for 4 h, after
which 100 µl of acidified sodium lauryl sulfate solution
(10% w/v in 0.01 N hydrochloric acid) was added to each
well. The plates were incubated for 16 h in a humidified
environment, and absorbance was read at 570 nm.
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Figure 1 shows the schematic of screening design used in
this study. Three anionic, cationic and nonionic surfactants,
which are approved for use in topical pharmaceutical
applications, were used to design a combinatorial binary
formulation library. The details for these chemicals are
given in Table I. The current study focuses only on binary
formulations and compares them to effectiveness and safety
of single-surfactant formulations. All formulations were
screened for antibacterial efficacy against E. Coli. Selected
formulations, which showed significant antibacterial activity
at the lowest concentration tested (0.025% w/v), were
screened for cytotoxicity against epithelial cells. This
concentration limit was primarily selected based on the
approved concentration of these surfactants in the GRAS
list. Binary formulations that exhibited higher LC50 values
compared to that of both of their component surfactants
were tested further for efficacy against B. thailandensis,a
model pathogen for melioidosis causing B. pseudomallei.
Figure 2A shows the antibacterial efficacy of all the
formulations tested in this study. The formulation index is
an arbitrary number which identifies each formulation.
Data shown are for each formulation at 4 different
concentrations. Antibacterial potency (AP) represents loss
of bacterial viability at the end of growth period, when the
bacteria are grown in presence of test formulation, and is
calculated as
AP ¼
Vo   V
Vo
X100
where, V is bacterial viability in the presence of test
formulation, and Vo is bacterial viability for negative control
(bacterial viability without surfactant formulations).
The tested formulations showed a range of efficacy
against E. coli with 36.3% completely suppressing the
bacterial growth during the test period, while 7% had no
significant effect on the growth (Fig. 2B). Approximately
38% were only mildly effective, with antibacterial activity of
less than 25%. A z-factor analysis was performed to assess
the validity of the antibacterial screening assay. The z-factor
was calculated to be 0.97, confirming that the assay exhibits
excellent screening qualities.
At a single surfactant level, the antibacterial activity was
typically proportional to the surfactant concentration with
cationic surfactants more potent than anionic surfactants,
which were, in turn, more potent than nonionic surfactants.
In binary combinations, the mixtures exhibited behavior
depending on the type of surfactants (Fig. 3). Mixtures of
anionic-anionic surfactants exhibited additive effects. For
example, mixtures of a moderately potent anionic surfac-
tant, SLS, with a weak anionic surfactant, ALS, led to
Fig. 1 High throughput screening
design for discovery of safe and
effective microbicides. Chemical
enhancers were selected from
FDA GRAS lists. Formulations
were screened in vitro for anti-
bacterial potential (AP) against
E. coli as model gram negative
pathogen and on adult human
keratinocyte cultures for
cytotoxicity
1267 Novel Topical Microbicides Through Combinatorial Strategiesformulations whose potency depended on the total SLS
concentration (Fig 3A). The relationship of potency with
the total SLS concentration in the formulation (open
circles, Fig 3A) overlapped with that of pure SLS (closed
circles, Fig 3A), suggesting that ALS acts merely as a
“diluent” in this case. Similar trends were seen for mixtures
of anionic and nonionic surfactants, for sample, SLS-S20
(Fig. 3B). Mixtures of anionic-cationic surfactants, for
example, SLS-CTC (Fig. 3C), exhibited very different
behavior. The activity of such mixtures did not exhibit a
clear correlation with the concentration of SLS. This can
be attributed to two reasons. First, in the case of SLS-CTC,
the latter has higher antibacterial activity and hence
dominates the behavior. Second, anionic and cationic
surfactants interact strongly with each other, leading to
unpredicted behavior. The data are also accompanied by
high error. The error is high for equi-mass mixtures of SLS-
CTC. The experimentally observed error for equi-mass
mixtures exceed 100% of the mean value, but drops to
about 20% for mixtures where one of the ingredients is
present in majority.
Mixtures of nonionic surfactants with other surfactants
(Figs. 3D-F) did not exhibit any peculiar behavior. Owing
to their relatively weak potency, the behavior of mixtures
was dominated by the other component. Behavior of
cationic surfactants (Figs. 3G-H), on the other hand,
exhibited entirely opposite effect. Owing to their strong
antibacterial activity, they dominated the behavior except
when anionic surfactants were used in the mixture, which
negated the potency of cationic surfactants due to charge
neutralization.
It was generally observed that for a formulation to
exhibit substantial antibacterial activity, at least one of the
ingredients must possess antibacterial activity on its own.
Further, the antibacterial activity of a formulation never
exceeded that of its pure antibacterial components at the
same concentration, thus showing a lack of synergy. This
behavior is very different from that observed for skin
permeation, where two permeation enhancers (including
surfactants) often formed synergistic mixture that yielded
significantly higher skin permeation enhancement com-
pared to that of their individual components (16).
We next assessed whether mixtures of surfactants,
though not capable of enhancing efficacy, are able to
mitigate toxicity. Selected formulations which exhibited
high antibacterial activity were tested for cytotoxicity
(Fig. 4A). The formulations can be divided into five regions
based on their antibacterial potency and toxicity behavior.
Formulations in region I possess low potency and high
toxicity. None of the formulations studied here belonged to
this region. Formulations in region II are weakly potent but
possess low cytotoxicity. Many binary formulations and
a majority of individual enhancer (red circles) studies
here belonged in this region. Region III corresponds to
formulations with intermediate potency and toxicity. This
region was relatively sparsely populated. Region IV
corresponds to formulations with high potency and high
toxicity. Region V, the most desirable region, corresponds
to high potency and low toxicity. Most individual chemicals
were found to localize either in region II (low potency-low
toxicity) or region IV (high potency-high toxicity). These
data are in agreement with the widely reported limitations
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Arora and Mitragotri 1268of single surfactants as microbicides and emphasize the
advantage of combinatorial screenings. In contrast, binary
formulations spanned a range of behavior, and some
exhibited departure from expected correlation between
efficacy and toxicity.
Formulations exhibiting high antibacterial potency
(>99%) and high keratinocyte viability (>70%) were further
analyzed. Interestingly, all these formulations comprised
mixtures of BZK and S20. A detailed analysis of these
mixtures revealed that antibacterial potency and cytotox-
icity exhibited systematic dependence on the composition
(Fig. 4B). S20 exhibited high cell viability but low antibac-
terial potency. BZK, on the other hand, exhibited high
potency but low cell viability. Mixtures of BZK:S20 in the
range of 30–70% BZK exhibited the ideal behavior. These
formulations were tested for stability and potency against
B. thailandensis. To further characterize their cytotoxicity,
their lethal concentrations (LC50) in keratinocytes were
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LC50 (0.00078 %w/v), whereas S20 exhibited negligible
toxicity and potency in the range of concentrations studied.
Binary compositions of BZK:S20 exhibited higher LC50
values compared to BZK alone, indicating that addition of
S20 to BZK decreases toxicity (Table II). However, addition
of S20 also led to decreased potency as judged by increased
MIC values. With two independent parameters (MIC
and LC50), it is difficult to determine the benefits offered
by binary formulations compared to single surfactant
formulations. Therefore, the ratio of these two quantities
(LC50/MIC) was used for determining the benefits of
these formulations as potential microbicide (Fig. 5). The
LC50/MIC ratios revealed that formulations of BZK and
S20 exhibit up to 3-fold higher LC50/MIC ratio compared
toBZKalone.Also,theLC50 values for all three formulations
were higher than those of BZK (p<0.05), proving their
advantage as microbicides over application of BZK alone.
DISCUSSION
Several studies have reported on the use of various
surfactants as potential microbicides (11–15). However, the
associated toxicity has significantly thwarted the application
of single-surfactant-based formulations. We have previously
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Table II List of MIC Values of Select Formulations Against B. thailandensis
and LC50 Values in Keratinocytes
Composition (BZK:S20) MIC ×10
4 (%w/v) LC50 ×10
4 (%w/v)
4:6 >100 2.83
5:5 15.63 2.04
6:4 9.38 1.89
7:3 9.11 1.80
10:0 7.48 0.48
0.25
0.3
0.35
0.4
*
**
*p<0.05
**p<0.01
0.05
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0.15
0.2
L
C
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0
/
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0
0 40 50 60 70 100
% BZK in Formulation
NS
Fig. 5 Safety and potency of selected formulations. LC50/MIC values of
selected BZK:S20 formulations. BZK is used as comparative control. Error
bars represent standard deviation (n=3).
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usinghigh-throughputscreeningfordiscoveringcombinations
with desired properties for drug and vaccine delivery (16,18).
These desired properties included high skin permeation
coupled with controlled toxicity. Results presented in this
study extend the strength of combinatorial high-throughput
screening to the discovery of surfactant formulations with
high antimicrobial activity and controlled toxicity. Specifi-
cally, we investigated whether it is possible to discover
surfactant combinationswhich are safer than single-surfactant
formulations for application as epithelial microbicides.
Over 300 binary formulations were tested for their
antimicrobial potency. More than one-third of the tested
formulations completely suppressed bacterial growth under
test conditions (Fig. 2), reaffirming the fact that antimicrobial
potency is not the limiting step in microbicide development.
Further, only those formulations which had surfactants
exhibiting strong antibacterial activity by themselves were
found to inhibit bacterial growth. This is a very interesting
observation, since unlike skin permeation, no synergistic
antimicrobial behavior was observed for any binary pair in
the library studied. None of the formulations exhibited higher
antimicrobial potency than their individual components.
Chemicals from different chemical categories may be included
infuturescreeningdesignsforgeneralizationofthisobservation.
It should be noted that for most formulations, the concen-
trationsofindividualsurfactantswerewithintheFDA-approved
limits for topical application, which increases the likelihood of
such formulations being safe for human applications.
Data in Fig. 4A showed that a significant proportion of
formulations were either safe but ineffective (region II) or
potent but toxic (region IV). An equally significant fraction
of formulations appeared to be strongly antibacterial, yet
potentially safe for epithelial application. This was higher
than the expected ratio, considering the scarcity of such
formulations when using single surfactants. Closer exami-
nation revealed that all these formulations were comprised
of mixtures of BZK and S20. The strong correlation between
epithelial toxicity and antimicrobial nature of surfactants, or
other small molecules, makes discovery of such formulations
extremely challenging. In the absence of fundamental
principles which can be used for designing new molecules or
discovering formulations with the desired safety and efficacy
characteristics, a high-throughput approach such as the one
described here can serve as a powerful tool for developing
such formulations as well as for collecting data which can aid
in our understanding of the toxicity challenge. The low
frequencyofoccurrenceofsafeandeffectiveformulations(less
than 1% of the total library in the current study) further
emphasizes the importance of high-throughput designs.
The study reported here is the first step in establishing
such combinatorial high-throughout screenings as a pow-
erful way for discovering unique formulations with desir-
able antimicrobial properties. The results discussed here
may be specific to the model pathogen and epithelial cell
line used in screening, but serve as a cost effective screening
method. Skin is a complex epithelial tissue composed of
several different types of cells. Keratinocyte cultures serve
as a screen to compare relative safety of various formula-
tions. However, the formulations discovered using such in
vitro systems should be tested in vivo using animals and finally
humans to establish safety and efficacy. Future studies will
focus on screening formulations targeted towards specific
pathogens of interest. The chemical library should also be
expanded to include more chemical categories with history
of topical applications, including fatty acids, esters and
amines. Studies should also focus on developing an
understanding of how surfactants interact with each other
and with cell and bacterial membranes so as to fundamen-
tally understand the mechanisms of synergy.
CONCLUSIONS
The results discussed here highlight a new approach to
surfactant-based microbicide development for epithelial
applications. A combination of commercially available
assays was adapted for high-throughput screening of
surfactant formulations, which resulted in discovery of
highly potent antimicrobial formulations. A small fraction
of screened formulations were proven to be safer than the
widely reported approach of using single surfactants, which
is often plagued by high toxicity. Lack of fundamental
understanding of interactions between formulation compo-
nents and epithelial tissue coupled with the low frequency
of occurrence of such novel formulations necessitate the use
of high-throughput screens such as the ones discussed here.
Further, the surfactant concentrations employed in this
study are within FDA-approved limits for most formula-
tions, thus increasing the likelihood of success during in vivo
trials. Future studies should focus on expanding the pool of
chemicals tested to other chemical classes beyond surfac-
tants and on validation of these results in vivo.
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